CA3071638A1 - Wnt compositions and methods of process from serum-free culturing conditions - Google Patents

Wnt compositions and methods of process from serum-free culturing conditions Download PDF

Info

Publication number
CA3071638A1
CA3071638A1 CA3071638A CA3071638A CA3071638A1 CA 3071638 A1 CA3071638 A1 CA 3071638A1 CA 3071638 A CA3071638 A CA 3071638A CA 3071638 A CA3071638 A CA 3071638A CA 3071638 A1 CA3071638 A1 CA 3071638A1
Authority
CA
Canada
Prior art keywords
wnt
polypeptide
composition
wnt3a
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3071638A
Other languages
English (en)
French (fr)
Inventor
Ping Yuan
Jill Helms
Ying Zhu
Bo Liu
Stefanie GASTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ankasa Regenerative Therapeutics Inc
Original Assignee
Ankasa Regenerative Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ankasa Regenerative Therapeutics Inc filed Critical Ankasa Regenerative Therapeutics Inc
Publication of CA3071638A1 publication Critical patent/CA3071638A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0031Serum-free culture media
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4705Regulators; Modulating activity stimulating, promoting or activating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40Regulators of development
    • C12N2501/415Wnt; Frizzeled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3071638A 2017-08-01 2018-08-01 Wnt compositions and methods of process from serum-free culturing conditions Pending CA3071638A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762539960P 2017-08-01 2017-08-01
US62/539,960 2017-08-01
US201862630448P 2018-02-14 2018-02-14
US62/630,448 2018-02-14
PCT/US2018/044886 WO2019028186A1 (en) 2017-08-01 2018-08-01 WNT COMPOSITIONS AND METHODS OF TREATMENT FROM SERUM-FREE CULTURE CONDITIONS

Publications (1)

Publication Number Publication Date
CA3071638A1 true CA3071638A1 (en) 2019-02-07

Family

ID=65234165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3071638A Pending CA3071638A1 (en) 2017-08-01 2018-08-01 Wnt compositions and methods of process from serum-free culturing conditions

Country Status (8)

Country Link
US (1) US20200399588A1 (enExample)
EP (1) EP3661475A4 (enExample)
JP (2) JP2020529845A (enExample)
CN (1) CN111182880B (enExample)
AU (1) AU2018309026A1 (enExample)
CA (1) CA3071638A1 (enExample)
GB (2) GB2610090B (enExample)
WO (1) WO2019028186A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116359367A (zh) * 2022-12-27 2023-06-30 绍兴市食品药品检验研究院 一种同位素内标高效液相色谱串联质谱法检测食品中γ-氨基丁酸的方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019121846A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
CN115702242A (zh) * 2020-04-20 2023-02-14 医药控股公司 一种改性的细菌透明质酸酶多肽、生产方法、药物组合物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0707472B1 (en) * 1993-07-08 2001-03-14 The Liposome Company, Inc. Method of controlling the size of liposomes
US6610316B2 (en) * 1997-05-30 2003-08-26 Shanbrom Technologies, Llc Disinfection by particle-bound and insolubilized detergents
WO2006036175A2 (en) * 2004-09-21 2006-04-06 Rhode Island Hospital, A Lifespan-Partner Wnt proteins and detection and treatment of cancer
US20070072239A1 (en) * 2005-09-26 2007-03-29 Wyeth Pharmaceutical compositions and methods of using secreted frizzled related protein
US8431532B2 (en) * 2010-06-28 2013-04-30 Five Prime Therepeutics, Inc. FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
US9873722B2 (en) * 2011-09-16 2018-01-23 Fate Therapeutics, Inc. Wnt compositions and therapeutic uses of such compositions
HK1212216A1 (en) * 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
AU2014329547B2 (en) * 2013-10-02 2019-05-16 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods for purification
JP7150604B2 (ja) * 2016-01-28 2022-10-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 無血清合成のためのwnt組成物及び方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116359367A (zh) * 2022-12-27 2023-06-30 绍兴市食品药品检验研究院 一种同位素内标高效液相色谱串联质谱法检测食品中γ-氨基丁酸的方法
CN116359367B (zh) * 2022-12-27 2023-08-25 绍兴市食品药品检验研究院 一种同位素内标高效液相色谱串联质谱法检测食品中γ-氨基丁酸的方法

Also Published As

Publication number Publication date
AU2018309026A1 (en) 2020-03-12
GB2581882A (en) 2020-09-02
GB202216232D0 (en) 2022-12-14
CN111182880A (zh) 2020-05-19
GB2610090B (en) 2023-05-17
GB2581882B (en) 2023-03-29
EP3661475A4 (en) 2021-06-02
JP2024120178A (ja) 2024-09-04
US20200399588A1 (en) 2020-12-24
GB2610090A (en) 2023-02-22
CN111182880B (zh) 2024-01-09
GB202001567D0 (en) 2020-03-18
EP3661475A1 (en) 2020-06-10
WO2019028186A1 (en) 2019-02-07
JP2020529845A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
JP2024120178A (ja) Wnt組成物および無血清培養条件からの処理の方法
CN103732628B (zh) 多价杂多聚体骨架设计和构建体
AU2018200971A1 (en) Protein expression enhancing polypeptides
US20220325238A1 (en) Wnt compositions and methods for serum-free synthesis
IL233024A (en) Proislet peptides containing optimization change and their pharmacy preparations
AU2019208196B2 (en) Wnt compositions and methods for purification
JP7600135B2 (ja) 組換えccnドメインタンパク質および融合タンパク質
WO2018058088A1 (en) Cell-associated secretion-enhancing fusion proteins
WO2019241628A1 (en) General amyloid interaction motif (gaim)
CN114945588A (zh) 抗缪勒氏管激素多肽
JP4995399B2 (ja) 切断されたbard1タンパク質、並びにその診断上及び治療上の利用
WO2020154363A1 (en) Engineered nucleobindin1-immunoglobulin fusion protein
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки
Ramyar et al. Expression, purification, and characterization of a human complement component C3 analog that lacks the C-terminal C345c domain
AU2004276687A1 (en) Method of cleaving polypeptide by using OmpT protease mutant

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230726